Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma

ConclusionCombination BMS-986,205 and nivolumab showed a manageable safety profile with durable benefit as first-line therapy in a meaningful subset of advanced HCC patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research